AWhat changed
The randomized BNT162b2 trial provided clinical evidence that an mRNA vaccine could prevent symptomatic COVID-19 under the trial’s conditions. It connected a molecular vaccine platform with a measured disease-prevention outcome.
Scientific scope
The randomized BNT162b2 trial provided clinical evidence that an mRNA vaccine could prevent symptomatic COVID-19 under the trial’s conditions. It connected a molecular vaccine platform with a measured disease-prevention outcome. Scope limitation: This record covers the original 2020 trial and its follow-up window, not current protection against later variants, all age groups or every rare adverse event. The 29 named publication authors are retained; the wider trial group and participating sites are not fully enumerated. Modified-RNA mechanism work remains a separate earlier contribution.
Evidence
Assessment uses the catalogue-linked source evidence for the stated contribution. This record covers the original 2020 trial and its follow-up window, not current protection against later variants, all age groups or every rare adverse event. The 29 named publication authors are retained; the wider trial group and participating sites are not fully enumerated. Modified-RNA mechanism work remains a separate earlier contribution.
Contributors
- The research collaboration listed in the linked record and source byline · SCIENCE: Collective scoped contribution. The complete recorded byline remains in the research record; this label does not collapse people into one individual.
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine — deposited bibliography
- Polack and colleagues: BNT162b2 trial publication
Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.
Full scientific record · Browse contribution grades · Request a correction